

UNIVERSITY
OF MIAMI



IRB 7.2 USER TRAINING

Presented by:
Joey Casanova, CIP
Associate Director for Educational Initiatives
Human Subject Research Office

UNIVERSITY
OF MIAMI



IRB 7 NAVIGATION



My Current Actions

Shortcuts
[My Inbox](#)
[Meetings](#)
[Reports](#)
[Help](#)
[Study Submission Guide](#)
[IRB Reviewer's Guide](#)
My Inbox

 Filter by

ID	Name	Date Created	<input checked="" type="checkbox"/> Date Modified	State	Coordinator
RNI00000005	_IRBSubmission - Mon Sep 16 11:32:47 EDT 2013	9/16/2013 11:32 AM	9/16/2013 11:32 AM	Pre-Submission	
20130011	UIRB	9/13/2013 12:51 PM	9/16/2013 11:20 AM	Pre-Submission	
20130010	test	9/13/2013 11:37 AM	9/13/2013 4:16 PM	Pre-Submission	
20130009	eIRB	9/13/2013 8:53 AM	9/13/2013 1:39 PM	Clarification Requested (Pre-Review)	James Holland (irbc)
CR00000001	Continuing Review for Study 20130001	9/10/2013 6:24 PM	9/12/2013 11:46 AM	Pre-Submission	James Holland (irbc)
RNI00000001	RNI Validation Test	9/6/2013 2:45 PM	9/6/2013 2:45 PM	Pre-Submission	

6 items page of 1 / page

IRB

▶ IRB Submissions

▶ IRB Meetings

▶ IRB Library

▶ IRB Reports

Shortcuts

My Inbox

Meetings

Reports

Help

Study Submission Guide

IRB Reviewer's Guide

In-Review		Active	Archived	New Information Reports		All Submissions		
ID	Name	<input type="checkbox"/> Date Modified	State	PI First Name	PI Last Name	Coordinator	Expiration Date	
20130004	TestStudy2- Update Consent Document	9/16/2013 11:31 AM	Approved	Rebecca	Simms (pi)	Holland (irbc)	9/12/2014	
20130012	External IRB	9/14/2013 3:17 PM	External IRB	Rebecca	Simms (pi)		9/28/2013	
20130001	Study Signature Validation Test	9/12/2013 11:40 AM	Approved	Rebecca	Simms (pi)	Holland (irbc)	9/10/2014	
20130006	Ext. IRB	9/11/2013 5:06 PM	External IRB	Rebecca	Simms (pi)	Holland (irbc)	9/13/2013	
20130005	UpdateConsentDocument2	9/11/2013 3:11 PM	Approved	Rebecca	Simms (pi)	Holland (irbc)	9/23/2014	

5 items < page 1 of 1 > 25 / page


Approved

20130004: TestStudy2- Update Consent Document

Entered IRB: 9/11/2013
Initial approval: 9/11/2013
Effective: 9/11/2013
Approval end: 9/12/2014
Modified: 9/16/2013 11:31 AM

Principal investigator: Rebecca Simms (pi)
Submission type: Initial Study
Primary contact: Rebecca Simms (pi)
IRB coordinator: James Holland (irbc)

IRB office: IRB A
Letter: Correspondence_for_20130004.



My Current Actions

- [View Study](#)
- [Printer Version](#)
- [View Differences](#)
- [Create Modification / CR](#)
- [Report New Information](#)
- [Copy Submission](#)
- [Add Comment](#)
- [Assign PI Proxy](#)
- [Update Billing Information](#)

Shortcuts

- [My Inbox](#)
- [Meetings](#)
- [Reports](#)
- [Help](#)
- [Study Submission Guide](#)
- [IRB Reviewer's Guide](#)

History	Project Contacts	Documents	Follow-on Submissions	Reviews	Snapsho
Filter by Activity <input type="text"/> <input type="button" value="Go"/> <input type="button" value="Clear"/> <input type="button" value="Advanced"/>					
Activity	Author	Acti			
<i>i</i> Continuing Review MODCR00000001 Withdrawn	Simms (pi), Rebecca	9/16/2			
<i>i</i> Continuing Review: MODCR00000001					
<i>i</i> Modification Closed	Simms (pi), Rebecca	9/16/2			
<i>i</i> Continuing Review: MODCR00000001					
<i>i</i> Modification MODCR00000001 Opened	Simms (pi), Rebecca	9/16/2			
<i>i</i> Modification: MODCR00000001					
<i>i</i> Continuing Review CR00000002 Withdrawn	Simms (pi), Rebecca	9/16/2			
<i>i</i> Continuing Review: CR00000002					
<i>i</i> Continuing Review CR00000002 opened	Simms (pi), Rebecca	9/16/2			
<i>i</i> Continuing Review: CR00000002					
<i>i</i> Copied Submission	Simms (pi), Rebecca	9/11/2			
<i>i</i> New Copy: 20130005 UpdateConsentDocument2					
<i>i</i> Letter Sent	Holland (irbc), James	9/11/2			

UNIVERSITY
OF MIAMI



THE NEW STUDY APPLICATION



CREATING A NEW STUDY

- New study information is entered into a series of online forms, the number of which may change based on the answers you provide
 - Note: A continuing review, modification, or RNI (reportable new information) submission can be handled similarly to a study
- Before you begin, gather files and information about your study such as:
 - Supporting information files
 - Financial interest status for each of your study team members
 - Contact information and IRB oversight information for external sites involved in the study

If you regularly create studies with a similar set of team members, you can save time by defining the default team members to be added to each study you create.

You can save time by defining the default list of ancillary reviewers to be added to each study you create.

A red asterisk () marks each required question. If you do not answer the question initially, you must answer it before you can submit the study for review*

Tips & Time Savers

COMPLETING THE SMART FORM

1. From My Inbox, click Create New Study.
 - *Note: If you do not see the Create New Study button, click the My Inbox link (upper right).*
2. Fill in the applicable boxes and answer the questions.
3. Click Continue to move to the next form.
4. When you reach the final page, click Finish to exit the study.
 - ***IMPORTANT! The study has not been submitted for review yet!***
 - *You can continue to edit the study until you submit it for review.*

Basic Information ?

1. * Title of study:

Title as listed in protocol

2. * Short title: ?

Abbreviated title for easy identification

3. * Brief description: ?

Summary of study

4. * Principal investigator:

Rebecca Simms (pi)

Select PI from a list of IRB7 users

5. * Does the investigator have a financial interest related to this research? ?

Yes No

Disclosures should be consistent with disclosures in DPS

6. * Will an external IRB act as the IRB of record for this study? ?

Yes No

Unless prior permission is granted, answer should be "No"

7. * Attach the protocol: (include the investigator protocol and full sponsor protocol)

Document	Category	Date Modified
There are no items to display		

Use one of these templates:

- HRP-503 - Protocol
- HRP-503 - Template Protocol - No Instructions

Sponsor's protocol should be uploaded here. For investigator-initiated research, use the protocol template to develop protocol

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Funding Sources

Continue >>

Funding Sources

1. **Identify each organization supplying funding for the study:**

Add

Funding Source	Sponsor's Funding ID	Grants Office ID	Attachments
----------------	----------------------	------------------	-------------

There are no items to display

**A list of known funding sources/sponsors will be available.
Contact the HSRO if a new source needs to be added.
Upload grant application or draft CTA as appropriate**

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Funding Sources

Continue >>

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Study Team Members

Continue >>

Study Team Members

1. **Identify each additional person involved in the design, conduct, or reporting of the research:**

Add

Name	Roles	Financial Interest	Involved in Consent	E-mail	Phone
------	-------	--------------------	---------------------	--------	-------

There are no items to display

Standard study teams may be associated with a PI. Please review to ensure that the study team members listed here are accurate

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Study Team Members

Continue >>

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Study Scope

Continue >>

Study Scope ?

1. * Are there external sites where the investigator will conduct or oversee the research?

Yes No [Clear](#)

Answer "yes" only if the UM PI is responsible for the conduct of this study at external sites

2. * Does the study do any of the following:

- Specify the use of an approved drug or biologic?
- Use an unapproved drug or biologic?
- Use a food or dietary supplement to diagnose, cure, treat, or mitigate a disease or condition?

Used for branching

Yes No [Clear](#)

3. * Does the study do any of the following:

- Evaluate the safety or effectiveness of a device?
- Use a humanitarian use device (HUD)?

Used for branching

Yes No [Clear](#)

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Study Scope

Continue >>

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Drugs ▾

Continue >>

Drugs ?

1. List all drugs, biologics, foods, and dietary supplements to be used in the study:

Add

Generic Name	Brand Name	Attachment Name
--------------	------------	-----------------

There are no items to display

List drugs, combinations, etc., to be studied
Investigator Brochures should be included here as well

2. * Will the study be conducted under any IND numbers? ? Yes No

Check yes if appropriate

If so, identify each IND:

Add

IND Number	IND Holder	Other Holder
------------	------------	--------------

There are no items to display

List as appropriate

3. Attach files: (such as IND or other information that was not attached for a specific drug) ?

Add

Document	Category	Date Modified
----------	----------	---------------

There are no items to display

Upload IND letter or other correspondence
from the FDA

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Drugs ▾

Continue >>

****This page will only appear if "yes" is selected in question 2 on the Study Scope page***

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Devices

Continue >>

Devices

1. * Select each device the study will use as an HUD or evaluate for safety or effectiveness:

Device	Humanitarian Use Device	Attachment Name
There are no items to display		

List devices to be studied
Any documentation, instructions, etc. associated with the use of the device would be uploaded here as well

2. * Device exemptions applicable to this study: 


IDE number
 HDE number
 Claim of abbreviated IDE (nonsignificant risk device)
 Exempt from IDE requirements

Check appropriate radio button

3. If applicable, identify each IDE and HDE number:

IDE / HDE Number	IDE/ HDE Holder	Other Holder
There are no items to display		

List as appropriate

4. Attach files: (such as IDE, HDE, or other information that was not attached for a specific device) 

Document	Category	Date Modified
There are no items to display		

Upload IDE letter or other correspondence from the FDA

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Devices

Continue >>

***This page will only appear if "yes" is selected in question 3 on the Study Scope page**



<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To:

Consent Forms and Recruitment Materials ▾

Continue >>

Consent Forms and Recruitment Materials

1. **Consent forms:** (include an HHS-approved sample consent document, if applicable) ?

Add

Document	Category	Date Modified
----------	----------	---------------

There are no items to display

Refer to the following templates and instructional documents:

- HRP-502 - Consent Document
- HRP-507 - Consent Document Short Form
- HRP-090 - Informed Consent Process for Research
- HRP-091 - Written Documentation of Consent

Upload ICF and other documents to be used during consent process

2. **Recruitment materials:** (add all material to be seen or heard by subjects, including ads) ?

Add

Document	Category	Date Modified
----------	----------	---------------

There are no items to display

Upload advertisements, flyers, patient letters and other documents to be used for recruitment

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To:

Consent Forms and Recruitment Materials ▾

Continue >>

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Supporting Documents ▾

Continue >>

Supporting Documents ?

Attach supporting files, naming them as you want them to appear in the approval letter:

Document	Category	Date Modified
----------	----------	---------------

There are no items to display

Upload any other documents not already included

Suggested attachments:

- Conflict of Interest Committee's determination for any financial interest related to the research
- Complete checklist of meeting Department of Energy requirements, if applicable
- Other study-related documents not attached on previous forms

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: Supporting Documents ▾

Continue >>

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: ▾

Finish

Final Page ?

NOTE: Clicking "Finish" does not submit the study. The PI must log in and click on the submit study link. NOTE: Only the PI may submit the study.

You have reached the end of the IRB submission form. Read the next steps carefully:

1. Click **Finish** to exit the form.
2. **Important!** To send the submission for review, the principal investigator must click **Submit** on the next page.

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To: ▾

Finish

CHECKING THE STUDY FOR ERRORS

- ***Automatic system error checking*** identifies omitted answers to required questions on the form when you click Continue
- ***Visually inspect the form*** to see if you missed:
 - Questions that are relevant to your study but not usually required
 - Documents that should be attached
- Use ***the Hide/Show Errors option*** to find and correct all errors before submitting the study
 - IRB 7.2 automatically checks for errors when PI attempts to submit the study
 - If you are filling out the forms on behalf of the PI, check the study for errors before the PI attempts to submit it

SUBMITTING THE STUDY FOR REVIEW

Important! Only the principal investigator can complete the following steps.

1. Log in to the system.
2. Make sure you are in My Inbox.
3. Click the name of the study to open it.
4. Click **Submit** from the My Current Actions list on the left.
5. Click **OK** to agree to the statement presented on the screen.
6. When prompted, log in again to verify your identity as the study's PI.
7. Click **Submit**.

WHAT TO EXPECT AFTER SUBMITTING

Submitting information to the IRB initiates a series of activities that may include:

- Review within your department
- Pre-review by an IRB staff member
- Review by the IRB committee or a designated reviewer
- Communication of the IRB decision to the investigator

*Any of these may lead to a request for the investigator to take further action, such as providing clarifications or modifying the study. **Whenever you need to act, you receive an e-mail notification, and the study appears in My Inbox when you log in to the IRB system.***

CHECKING THE STATUS OF YOUR STUDY

- You can see a diagram showing the state of your study by opening the study. For example:



- You can easily open your study from one of the following lists (depending on its status):
 - My Inbox
 - IRB In-Review Studies
 - IRB Active Studies

RESPONDING TO A REQUEST FOR CLARIFICATIONS OR MODIFICATIONS

*The IRB may request clarifications or require changes before research can begin. The PI and the study's primary contact will receive an e-mail and the study will appear in **My Inbox** for each member of the study team.*

To view the details of the request and respond with the changes:

1. From **My Inbox**, click the name of the study to open it
2. Locate the details of the request
3. Edit the study to incorporate changes as needed
4. Click **Submit Changes** to return the study to the reviewers
 - The Submit Changes form gives you space to type a response to the requests and to attach a file
5. Click **OK**. The study will return to the review process

UNIVERSITY
OF MIAMI



THE MODIFICATION/ CONTINUING REVIEW FORM



<< Back

Save | Print...

Continue >>

Modification / Continuing Review

* What is the purpose of this submission?

- Continuing Review
 - Modification
 - Modification and Continuing Review
- Clear

Select type of submission

Modification Scope:

- Study team member information
- Other parts of the study

NOTE: This question will not appear if "Continuing Review" is selected above

Active modification for this study

Modification type(s)

<< Back

Save | Print...

Continue >>

<< Back

Continuing Review / Study Closure Information

Continue >>

Continuing Review / Study Closure Information

1. * Specify enrollment totals:

	Subjects Enrolled	Total	Since Last Approval
At this investigator's sites:	<input type="text"/>	<input type="text"/>	<input type="text"/>
Study-wide:	<input type="text"/>	<input type="text"/>	

Numbers reported here must be consistent with prior reports and, if applicable, Velos

2. Research milestones: (select all that apply)

- Study is permanently closed to enrollment
- All subjects have completed all study-related interventions
- Collection of private identifiable information is complete
- Analysis of private identifiable information is complete
- Remaining study activities are limited to data analysis
- Study remains active only for long-term follow-up of subjects


Indicate current state of the study

Important! If the first four research milestones above are complete, the study will be closed to discontinue IRB oversight.

3. * Do any investigators or research staff have a financial interest related to the research that was not described in a previous application?

Study remains active only for long-term follow-up of subjects

Important! If the first four research milestones above are complete, the study will be closed to discontinue IRB oversight.

3. * **Do any investigators or research staff have a financial interest related to the research that was not described in a previous application?** 

If a COI was disclosed at initial submission, or there are no COIs, select "No"

Yes No [Clear](#)

NO subjects withdrew from the study

NO unanticipated problems involving risks to subjects or others

NO complaints about the study

NO publications in the literature relevant to risks or potential benefits

NO interim findings

NO multi-center trial reports

NO data safety monitoring reports

NO regulatory actions that could affect safety and risk assessments


NO other relevant information regarding this study, especially information about risks

In the opinion of the PI, the risks and potential benefits are unchanged

All modifications to the protocol have been submitted to the IRB

All problems that require prompt reporting to the IRB have been submitted

Select all that apply

5. **Attach supporting documents:** (include an explanation of each item left unchecked above) 

Name

There are no items to display

Examples: enrollment summaries, summaries of AEs not requiring immediate reporting, summaries of deviations not requiring immediate reporting, DSMB reports, grant progress reports, sponsor letters re: enrollment, etc.

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To:

Continuing Review / Study Closure Information ▾

Continue >>

Modification Information

1. Study enrollment status:

- Subjects are currently enrolled
- Study is permanently closed to enrollment
- All subjects have completed all study-related interventions
- Collection of private identifiable information is complete

Indicate current state of study

2. Notification of subjects: (check all that apply)

- Current subjects will be notified of these changes
- Former subjects will be notified of these changes

Indicate whether PI intends to notify subjects

Attach files: If notifying subjects, add a description of how they will be notified to the Supporting Documents page.

3. * Summarize the modifications:

List any changes that are UM-specific

Study-wide modifications that are described in a sponsor's amendment do not need to be included here. Study teams may simply state "Refer to sponsor's summary of changes (or other appropriate document)"

**IRB 7 WILL AUTOMATICALLY
OPEN A MODIFIABLE
VERSION OF THE STUDY
FORM**

**ANY CHANGES LISTED IN THE
AMENDMENT FORM
SHOULD BE MADE TO THIS
VERSION OF THE STUDY
FORM**

You Are Here:  TestStudy2- Update Consent Doc... >  Continuing Review for Study 20...

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To:

Finish

NOTE: Clicking "Finish" does not submit the continuing review/modification. The PI must log in and click on the submit link. NOTE: Only the PI may submit the continuing review/modification.

Final Page

You have reached the end of the IRB submission form. Read the next steps carefully:

1. Click **Finish** to exit the form.
2. **Important!** To send the submission for review, the principal investigator must click **Submit** on the next page.

<< Back

Save | Exit | Hide/Show Errors | Print... | Jump To:

Finish

UNIVERSITY
OF MIAMI



THE REPORTABLE NEW INFORMATION FORM



Reportable New Information

When viewing items in your Inbox or on the IRB Workspace, RNI Short Title will show up under the "Name" column

1. **RNI short title:** (uniquely identify this new information report)

2. * **Date you became aware of the information:**

List date study team became aware of the RNI

3. **Identify the categories that represent the new information:** (check all that apply)

- Risk:** Information that indicates a new or increased risk, or a safety issue. For example:
- a. New information (e.g., an interim analysis, safety monitoring report, publication in the literature, sponsor report, or investigator finding) indicates an increase in the frequency or magnitude of a previously known risk, or uncovers a new risk.
 - b. An investigator brochure, package insert, or device labeling is revised to indicate an increase in the frequency or magnitude of a previously known risk, or to describe a new risk.
 - c. Withdrawal, restriction, or modification of a marketed approval of a drug, device, or biologic used in a research protocol.
 - d. Protocol violation that harmed subjects or others or that indicates subjects or others might be at increased risk of harm.
 - e. Complaint of a subject that indicates subjects or others might be at increased risk of harm or at risk of a new harm.
 - f. Any changes significantly affecting the conduct of the research, frequency, and characteristics of the study population.
 - b. A harm is "**probably related**" to the research procedures if, in the opinion of the investigator, the research procedures more likely than not caused the harm.

RNI includes unanticipated problems, newly identified risks, adverse events (unexpected and probably related), deviations and violations, audit or monitoring results, etc.

RNIs do not include expected or unrelated AEs, IND Safety Reports, Translations, Sponsor Letters without impact on risks, etc.

- Non-compliance:** Non-compliance with the federal regulations governing human research or with the requirements or determinations of the IRB, or an allegation of such non-compliance

b. A harm is "**probably related**" to the research procedures if, in the opinion of the investigator, the research procedures more likely than not caused the harm.

- Non-compliance:** Non-compliance with the federal regulations governing human research or with the requirements or determinations of the IRB, or an allegation of such non-compliance.
- Audit:** Audit, inspection, or inquiry by a federal agency.
- Report:** Written reports of study monitors.
- Researcher error:** Failure to follow the protocol due to the action or inaction of the investigator or research staff.
- Confidentiality:** Breach of confidentiality.
- Unreviewed change:** Change to the protocol taken without prior IRB review to eliminate an apparent immediate hazard to a subject.
- Incarceration:** Incarceration of a subject in a study not approved by the IRB to involve prisoners.
- Complaint:** Complaint of a subject that cannot be resolved by the research team.
- Suspension:** Premature suspension or termination of the research by the sponsor, investigator, or institution.
- Unanticipated adverse device effect:** Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

Important! Information that does not fit into one of the categories above does not need to be reported to the IRB as new information.

4. * **Briefly describe the new information:**

Summary of RNI

5. **In the PI's opinion:**

5. In the PI's opinion:

a. * Does this information indicate a new or increased risk, or a safety issue?

Yes No [Clear](#)

b. * Does the study need revision?

Yes No [Clear](#)

Select Yes or No based on PI's review of the RNI

c. * Does the consent document need revision?

Yes No [Clear](#)

If revisions are required, describe them above and submit a study modification for review.

6. Related Studies:

ID	Short Title	Investigator	State	IRB Office
----	-------------	--------------	-------	------------

There are no items to display

You will be able to list as many studies as are affected. (E.g. PI is involved in multiple studies involving the same drug.)

7. Attach files containing supporting information:

Name

There are no items to display

Upload documents as appropriate

<< Back

Save | Print...

Continue >>



UNIVERSITY
OF MIAMI



THE PROTOCOL TEMPLATE



USING THE INVESTIGATOR PROTOCOL TEMPLATE

- Guidance to investigators will be italicized and should be deleted
- Certain sections of the template *may not* be applicable
- Indicate in your inclusion criteria the following populations of subjects :
 - Adults unable to provide legally effective consent
 - Individuals who are not yet adults (infants, children, teenagers)
 - Pregnant women
 - Prisoners
- Contact the HSRO for information about:
 - Using a community-based participatory research design
 - Use of community advisory boards
 - Use of participant advocates
 - Partnerships with community-based organizations

SAMPLE PROTOCOL TEMPLATE

SECTION-BY-SECTION

1. Protocol Title
2. IRB Review History
 - Details of any prior review including IRB name, dates and contact info
3. Objectives
 - Purpose, specific aims and objectives
4. Background
5. Inclusion and Exclusion Criteria
 - Populations with additional requirements: adults unable to consent; infants, children, teenagers; pregnant women; prisoners
6. Number of Subjects
7. Study-Wide Recruitment Methods
8. Study Timelines
9. Study Endpoints
10. Procedures Involved
11. Data and Specimen Banking
12. Data Management
13. Provisions to Monitor the Data to Ensure the Safety of Subjects
14. Withdrawal of Subjects
15. Risks to Subjects
16. Potential Benefits to Subjects

SAMPLE PROTOCOL TEMPLATE

SECTION-BY-SECTION

17. Vulnerable Populations
18. Multi-Site Research
 - Procedures for communication among engaged sites
19. Community-Based Participatory Research
20. Sharing of Results with Subjects
21. Setting
22. Resources Available
23. Prior Approvals
 - e.g. schools, external sites, funding agency, laboratory, radiation safety, biosafety
24. Recruitment Methods
25. Local Number of Subjects
26. Confidentiality
27. Provisions to Protect the Privacy Interests of Subjects
28. Compensation for Research-Related Injury
29. Economic Burden to Subjects
30. Consent Process
 - Non-English speaking subjects
 - Waivers or Alternation of Consent Process
 - Cognitively Impaired Adults
 - Adults Unable to Consent
31. Process to Document Consent in Writing
32. Drugs or Devices

CREATING A CONSENT DOCUMENT

- HSRO will provide a Template Consent Document
- All consent documents must contain all of the required and all additional appropriate elements of informed consent disclosure
 - Standard language for studies that pay \$600 or more
 - Standard language for Category B devices
 - Standard language for UHealth studies
- We recommend that you date the revisions of your consent documents to ensure that you use the most recently approved version

THANK YOU!



Joey Casanova, CIP
Associate Director for Educational Initiatives
jcasanova@med.miami.edu

305-243-9232

UNIVERSITY
OF MIAMI

